Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by ledrogon Aug 09, 2019 3:24pm

271 Views

Post# 30012493

A chart worth looking at....

A simple chart that shows how AMRN traded from July 1st 2018 up until Sept 21....before they announced the REDUCE IT trial results. Some rallies, some drops....nothing that could be seen as predictive about the outcome of their trial I don't think.

Looking at how AMRN traded last year ahead of their results reminds me not to get too excited when RVX climbs, or too worried when it drops....Here's hoping for successful BETonMACE results and then at least a repeat of how AMRN traded afterwards, or more.

User image